Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Fineline Cube Jan 12, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China

Fineline Cube Sep 28, 2023

Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...

Policy / Regulatory

Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...

Policy / Regulatory

Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments

Fineline Cube Sep 27, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene...

Company Deals

Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies

Fineline Cube Sep 27, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...

Company Drug

Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast

Fineline Cube Sep 27, 2023

Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...

Company Drug

Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment

Fineline Cube Sep 27, 2023

Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...

Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment

Fineline Cube Sep 27, 2023

United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...

Company Drug

BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02

Fineline Cube Sep 27, 2023

BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...

Company Drug

Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China

Fineline Cube Sep 27, 2023

The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...

Company

Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs

Fineline Cube Sep 27, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...

Company Deals

Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership

Fineline Cube Sep 27, 2023

Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application...

Company

Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus

Fineline Cube Sep 27, 2023

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first...

Company Medical Device

CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting

Fineline Cube Sep 27, 2023

China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative...

Policy / Regulatory

Hunchun Port Designated as Medical Materials Import Port by NMPA and GAC

Fineline Cube Sep 27, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have jointly released...

Company

Baxter Appoints Wu Xin as China General Manager Amid Spin-Off of Kidney Care Business

Fineline Cube Sep 27, 2023

Baxter (NYSE: BAX), a leading provider of healthcare products, has announced the appointment of Wu...

Company

China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress

Fineline Cube Sep 27, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report...

Company Drug

EC Approves AbbVie’s Tepkinly for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Fineline Cube Sep 26, 2023

The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its bispecific...

Company Drug

Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment

Fineline Cube Sep 26, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company

Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report

Fineline Cube Sep 26, 2023

Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has...

Posts pagination

1 … 407 408 409 … 606

Recent updates

  • Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets
  • Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Others

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.